The DOI matches its Crossref record; 63 of the 65 references it cites were found in a registry or an index.
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Open accessAbstract
Enhancers, critical determinants of cellular identity, are commonly recognized by correlative chromatin marks and gain-of-function potential, although only loss-of-function studies can demonstrate their requirement in the native genomic context. Previously, we identified an erythroid enhancer of human BCL11A, subject to common genetic variation associated with the fetal haemoglobin level, the mouse orthologue of which is necessary for erythroid BCL11A expression. Here we develop pooled clustered regularly interspaced palindromic repeat (CRISPR)-Cas9 guide RNA libraries to perform in situ saturating mutagenesis of the human and mouse enhancers. This approach reveals critical minimal features and discrete vulnerabilities of these enhancers. Despite conserved function of the composite enhancers, their architecture diverges. The crucial human sequences appear to be primate-specific. Through editing of primary human progenitors and mouse transgenesis, we validate the BCL11A erythroid enhancer as a target for fetal haemoglobin reinduction. The detailed enhancer map will inform therapeutic genome editing, and the screening approach described here is generally applicable to functional interrogation of non-coding genomic elements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The authors flow-sorted the edited cells on the basis of the BCL11A-dependent switch to fetal haemoglobin, sequenced guides enriched in cells that had or hadn’t switched, and on the basis of those enrichments, successfully identified a primate-specific GATA1 motif critical for that enhancer’s function.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Cas9 introduces a targeted double-strand break, which is repaired by homology-directed repair using the donor templates, resulting in the incorporation of a single variant at the endogenous genomic locus (54, 55).”
From Massively parallel functional genomic assays in endocrinology: from promise to delivery (2026) · cites this paper as [54]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The first such screen targeted gRNAs to effectively tile small indels across a known cluster of enhancers of BCL11A195.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Canver et al 9 recently showed BCL11A enhancer disruption by CRISPR/Cas9 could induce fetal haemoglobin in both mice and primary human erythroblast cells.”
From What is CRISPR/Cas9? (2016) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The initial CRISPR screens of regulatory elements delivered an individual gRNA per cell195.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
The cited source says what the claim attributes to it.
In the citing paper
“To date, all such screens use Cas9-induced perturbations, including active Cas9 for sequence disruption195, or nuclease dead-Cas9 (dCas9) tethered to an epigenetic repressor105 or activator domain92.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
In the citing paper
“In contrast, nine recently published CRISPR screens of noncoding sequences cumulatively studied regulatory effects on a total of 17 genes (Canver et al., 2015; Diao et al., 2016, 2017; Fulco et al., 2016; Gasperini et al., 2017; Klann et al., 2017; Korkmaz et al., 2016; Rajagopal et al., 2016; Sanjana et al., 2016).”
From A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens (2019) · cites this paper as Canver et al., 2015
In the citing paper
“First, they focus on the regulation of a single gene per experiment, typically entailing the development of a gene-specific assay.”
From A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens (2019) · cites this paper as Canver et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationRNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Self-citationGenome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationHistone H3K27ac separates active from poised enhancers and predicts developmental state
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016071107 · Cited by 4,302
FIMO: scanning for occurrences of a given motif
Grant, C. E., Bailey, T. L., & Noble, W. S. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr064 · Cited by 4,247
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Systematic Localization of Common Disease-Associated Variation in Regulatory DNA
Maurano, M. T., Humbert, R., Rynes, E., Thurman, R. E., Haugen, E., Wang, H., Reynolds, A. P., Sandstrom, R., Qu, H., Brody, J., et al. (2012) · Science · doi:10.1126/science.1222794 · Cited by 3,716
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
Self-citation
Cited by
Sorted by citations
Items 601–700 of 883
Understanding variants of unknown significance: the computational frontier
Fu, X., & Rabadán, R. (2024) · The Oncologist · doi:10.1093/oncolo/oyae103 · Cited by 7
THERAPEUTIC GENE EDITING FOR HEMOGLOBINOPATHIES
Testa, U., Leone, G., & Cappellini, M. D. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.068 · Cited by 8
CRISPR-based gene therapy for the induction of fetal hemoglobin in sickle cell disease
McManus, M. P., Frangoul, H., & Steinberg, M. H. (2024) · Expert Review of Hematology · doi:10.1080/17474086.2024.2429605 · Cited by 8
Lin, H., Ye, X., Chen, W., Hong, D., Liu, L., Chen, F., Sun, N., Ye, K., Hong, J., Zhang, Y., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkae1323 · Cited by 7
Yannaki, E., Psatha, N., Παπαδοπούλου, Α., Athanasopoulos, T., Gravanis, A., Roubelakis, M. G., Tsirigotis, P. D., Anagnostopoulos, Α., Anagnou, N. P., & Vassilopoulos, G. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.196 · Cited by 6
A systematic review of clinical trials for gene therapies for β-hemoglobinopathy around the world
Rós, F. A., Couto, S. C. F., Milhomens, J., Ovider, I., Tozatto‐Maio, K., Jennifer, V., Ramos, R. N., Picanço‐Castro, V., Kashima, S. H., Calado, R. T., et al. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.05.006 · Cited by 9
Ikwuka, A. O., Musa, S., Udeh, F. C., Musa, A. A., & Chukwuezie, U. C. (2023) · American Journal of Medical Science and Innovation · doi:10.54536/ajmsi.v2i2.1760 · Cited by 7
Yang, M. G., & West, A. E. (2016) · Europe PMC (PubMed Central) · Cited by 7
Maroofi, N., Azarkeivan, A., Banihashemi, S., Mohammadparast, S., Aghajanirefah, A., & Banan, M. (2017) · Pharmacogenomics · doi:10.2217/pgs-2017-0019 · Cited by 7
CAMIO: a transgenic CRISPR pipeline to create diverse targeted genome deletions in Drosophila
Chen, H.-M., García‐Marqués, J., Sugino, K., Wei, D., Miyares, R. L., & Lee, T. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa177 · Cited by 8
Screening Regulatory Element Function with CRISPR/Cas9-based Epigenome Editing
Klann, T. S., Crawford, G. E., Reddy, T. E., & Gersbach, C. A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7774-1_25 · Cited by 7
Human cellular model systems of β-thalassemia enable in-depth analysis of disease phenotype
Daniels, D. E., Ferrer-Vicens, I., Hawksworth, J., Andrienko, T. N., Finnie, E. M., Bretherton, N. S., Ferguson, D. C. J., Oliveira, A. S. F., Szeto, J.-Y. A., Wilson, M. C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41961-9 · Cited by 8
Therapeutics for sickle cell disease intravascular hemolysis
Xue, J., & Li, X. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1474569 · Cited by 8
Multi-locus CRISPRi targeting with a single truncated guide RNA
Moore, M. M., Wekhande, S., Issner, R., Collins, A., Cruz, A. J., Liu, Y. V., Javed, N. M., Casaní-Galdón, S., Buenrostro, J. D., Epstein, C. B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56144-x · Cited by 6
Nonclinical evaluation of renizgamglogene autogedtemcel for SCD and TDT
Marco, E., Sousa, P., Janoudi, T., Dreuzy, E. D., Heath, J. M., Viswanathan, R., Zuris, J. A., Gotta, G. M., Giannoukos, G., Hansen, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.09.031 · Cited by 6
Kansal, R. (2025) · Genes · doi:10.3390/genes16111367 · Cited by 6
Li, J., Lv, A., Chen, M., Xu, L., & Huang, H. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05508-8 · Cited by 6
Yao, Y., Zhou, Z., Wang, X., Liu, Z., Zhai, Y., Chi, X., Du, J., Luo, L., Zhao, Z., Wang, X., et al. (2024) · Cell Genomics · doi:10.1016/j.xgen.2024.100583 · Cited by 6
Gene Therapies for Sickle Cell Disease
Weaver, S. B., Singh, D., & Wilson, K. M. (2024) · Journal of Pharmacy Technology · doi:10.1177/87551225241268742 · Cited by 6
Martyn, G. E., Doerfler, P. A., Yao, Y., Quinlan, K. G. R., Weiss, M. J., & Crossley, M. (2024) · Journal of sickle cell disease. · doi:10.1093/jscdis/yoae008 · Cited by 7
Van, R. S., Pan, X., Rostami, S., Liu, J., Agarwal, P. K., Brooks, B. R., Rajan, R., & Shao, Y. (2024) · Biochemistry · doi:10.1021/acs.biochem.4c00651 · Cited by 6
Sui, C., Wan, H., Han, W., Zhou, L., & Wang, S. (2022) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023666220307104501 · Cited by 6
Ban, Q., Lee, J., Shi, Z., Lu, D., Qiao, L., Yang, P., Li, X., Cheng, H., Zhang, M., Hou, J., et al. (2022) · Nano Today · doi:10.1016/j.nantod.2022.101659 · Cited by 6
Structural insights into the DNA-binding mechanism of BCL11A: The integral role of ZnF6
Viennet, T., Yin, M., Jayaraj, A., Kim, W., Sun, Z.-Y. J., Fujiwara, Y., Zhang, K., Seruggia, D., Seo, H., Dhe‐Paganon, S., et al. (2024) · Structure · doi:10.1016/j.str.2024.09.022 · Cited by 8
Self-citationTarget Discovery for Precision Medicine Using High-Throughput Genome Engineering
Guo, X., Chitale, P., & Sanjana, N. E. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63904-8_7 · Cited by 8
Self-citationPenzar, D., Zinkevich, A. O., Vorontsov, I. E., Sitnik, V. V., Favorov, A. V., Makeev, V. J., & Kulakovskiy, I. V. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.01078 · Cited by 6
Computational Methods for Analysis of Large-Scale CRISPR Screens
Lin, X., Chemparathy, A., Russa, M. F. L., Daley, T., & Qi, L. S. (2020) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-020520-113523 · Cited by 7
Engineering precision therapies: lessons and motivations from the clinic
Xie, M., Viviani, M., & Fussenegger, M. (2020) · Synthetic Biology · doi:10.1093/synbio/ysaa024 · Cited by 6
Impact of a grant program to spur advances in sickle cell disease research
Escobar-Alvarez, S., & Myers, E. R. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005709 · Cited by 5
Is There a Role for Pharmacogenetics in the Treatment of Sickle Cell Disease?
Wonkam, A. (2017) · Pharmacogenomics · doi:10.2217/pgs-2016-0007 · Cited by 6
Genome editing for blood disorders: state of the art and recent advances
Romito, M., Rai, R., Thrasher, A. J., & Cavazza, A. (2019) · Emerging Topics in Life Sciences · doi:10.1042/etls20180147 · Cited by 7
Massively parallel disruption of enhancers active during human corticogenesisPreprint
Geller, E. T., Gockley, J., Emera, D., Uebbing, S., Cotney, J. L., & Noonan, J. P. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/852673 · Cited by 6
Golov, A. K., Gavrilov, A. A., Kaplan, N., & Razin, S. V. (2023) · eLife · doi:10.7554/elife.91596 · Cited by 5
CRISPR-Cas technologies: Emerging tools from research to clinical application
Hyeon, H., Hwang, S., Luo, Y., Shin, E., Yeom, J., Kim, H., Ryu, M., & Lee, K. (2025) · The Journal of Microbiology · doi:10.71150/jm.2504012 · Cited by 7
Advances in β-Thalassemia Gene Therapy: CRISPR/Cas Systems and Delivery Innovations
Liu, H., & Zhang, P. (2025) · Cells · doi:10.3390/cells14201595 · Cited by 8
Papaioannou, N. Y., Patsali, P., Naiisseh, B., Papasavva, P. L., Koniali, L., Kurita, R., Nakamura, Y., Christou, S., Sitarou, M., Mussolino, C., et al. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1141618 · Cited by 5
Self-citationWongborisuth, C., Innachai, P., Saisawang, C., Tubsuwan, A., Jearawiriyapaisarn, N., Kaewprommal, P., Piriyapongsa, J., Chiangjong, W., Anurathapan, U., Songdej, D., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-10791-8 · Cited by 5
CRISPR/Cas9 Ablated BCL11A Unveils the Genes with Possible Role of Globin Switching
Motlagh, F. M., Soleimanpour‐Lichaei, H. R., Shamsara, M., Etemadzadeh, A., & Modarressi, M. H. (2023) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2023.074 · Cited by 5
Vitamin C derivative/AA2P promotes erythroid differentiation by upregulating CA1
Tan, X., Li, M., Liang, Y., Ruan, X., Zhang, Z., & Fang, X. (2023) · Life Medicine · doi:10.1093/lifemedi/lnad043 · Cited by 5
Role of gene therapy in sickle cell disease
Raghuraman, A., Lawrence, R., Shetty, R., Avanthika, C., Jhaveri, S., Pichardo, B. V., & Mujakari, A. (2024) · Disease-a-Month · doi:10.1016/j.disamonth.2024.101689 · Cited by 5
Clinically‐oriented proteomic investigation of sickle cell disease: Opportunities and challenges
Renella, R. (2016) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201500133 · Cited by 5
Therapeutic Gene Editing with CRISPR
Hahn, E., & Hiemenz, M. (2020) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2020.02.008 · Cited by 5
Zhou, Y., & Wei, W. (2016) · Nature Biotechnology · doi:10.1038/nbt.3477 · Cited by 5
Back to the Future: Mutant Hunts Are Still the Way To Go
Winston, F., & Koshland, D. E. (2016) · Genetics · doi:10.1534/genetics.115.180596 · Cited by 5
Pratt, H., & Weng, Z. (2018) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2018.09.002 · Cited by 4
A statistical framework for predicting critical regions of p53-dependent enhancers
Niu, X., Deng, K., Liu, L., Yang, K., & Hu, X. (2020) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa053 · Cited by 5
Many rare genetic variants have unrecognized large-effect disruptions to exon recognitionPreprint
Cheung, R., Insigne, K. D., Yao, D., Burghard, C. P., Jones, E. M., Goodman, D. B., & Kosuri, S. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/199927 · Cited by 5
Multipartite super-enhancers function in an orientation-dependent mannerPreprint
Kassouf, M. T., Francis, H. S., Gosden, M. E., Suciu, M., Downes, D. J., Harrold, C. L., Larke, M., Oudelaar, A. M., Cornell, L., Blayney, J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.14.499999 · Cited by 6
Golov, A. K., Gavrilov, A. A., Kaplan, N., & Razin, S. V. (2023) · doi:10.7554/elife.91596.1 · Cited by 4
Epigenetic Regulation of Erythropoiesis: From Developmental Programs to Therapeutic Targets
Vasiloudis, N.-I., Paschoudi, K., Beta, C., Georgolopoulos, G., & Psatha, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136342 · Cited by 8
Hematopoietic stem cell therapy with gene modification to treat sickle cell disease
Ball, J., Bradley, A., Le, A., Tisdale, J. F., & Uchida, N. (2025) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szaf042 · Cited by 7
Almasoudi, H. H. (2025) · Current Research in Translational Medicine · doi:10.1016/j.retram.2025.103513 · Cited by 5
CRISPR/Cas9 Approaches to Investigate the Noncoding Genome
Seruggia, D., & Montoliu, L. (2016) · Springer eBooks · doi:10.1007/978-3-319-34148-4_2 · Cited by 4
Efficient and error-free correction of sickle mutation in human erythroid cells using prime editor-2
George, A., Ravi, N. S., Prasad, K. M., Panigrahi, L., Koikkara, S., Rajendiran, V., Devaraju, N., Paul, J., Pai, A. A., Nakamura, Y., et al. (2022) · Frontiers in Genome Editing · doi:10.3389/fgeed.2022.1085111 · Cited by 6
Self-citationRNA Modifications in Cancer Stem Cell Biology
Cerneckis, J., Cui, Q., Liu, W., & Shi, Y. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-45654-1_2 · Cited by 4
Yang, J.-P., Toughiri, R., Gounder, A. P., Scheibe, D., Petrus, M. J., Fink, S. J., Vallée, S., Kenniston, J. A., Papaioannou, N., Langston, S., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307049 · Cited by 5
High-throughput CRISPR approaches: New solutions for challenging problems
Bindal, G., Misra, C. S., Singh, M. K., Rangu, S. S., Pandey, N., & Rath, D. (2025) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2025.118245 · Cited by 4
Mechanisms and causality in molecular diseases
Keenan, S. E., & Shvartsman, S. Y. (2017) · History & Philosophy of the Life Sciences · doi:10.1007/s40656-017-0162-1 · Cited by 4
Approches haut débit pour l’étude des séquences cis-régulatrices
España, A. P., Santiago‐Algarra, D., Pradel, L. C., & Spicuglia, S. (2017) · Biologie Aujourd hui · doi:10.1051/jbio/2018015 · Cited by 4
Sethi, S., Vorontsov, I. E., Kulakovskiy, I. V., Greenaway, S., Williams, J. A., Makeev, V. J., Brown, S. D. M., Simon, M. M., & Mallon, A. (2020) · BMC Genomics · doi:10.1186/s12864-020-07109-5 · Cited by 4
A unifying statistical framework to discover disease genes from GWASs
McManus, J. N. J., Lovelett, R. J., Lowengrub, D., & Christensen, S. (2023) · Cell Genomics · doi:10.1016/j.xgen.2023.100264 · Cited by 5
Kaur, K. K. (2022) · Current Trends in Biomedical Engineering & Biosciences · doi:10.19080/ctbeb.2022.20.556046 · Cited by 4
Shaping the nebulous enhancer in the era of high-throughput assays and genome editing
Ho, E. Y.-K., Cao, Q., Gu, M., Chan, R. W.-L., Wu, Q., Gerstein, M., & Yip, K. Y.-L. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz030 · Cited by 4
Thalassemia: a look to the future
Nathan, D. G. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13002 · Cited by 4
Gao, Y., Du, X., Zeng, J., Wu, R., Chen, Y., Li, F., Li, W., Zhou, H. K., Yang, Y., & Pei, Z. (2018) · Oncology Letters · doi:10.3892/ol.2018.8638 · Cited by 4
Simeonov, D. R., Gowen, B. G., Boontanrart, M. Y., Roth, T. L., Lee, Y., Chan, A. Y. K., Nguyen, M. L. T., Gate, R. E., Subramaniam, M., Woo, J. M., et al. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/091843 · Cited by 4
Integrative analysis and refined design of CRISPR knockout screensPreprint
Chen, C.-H., Li, W., Xiao, T., Xu, H., Jiang, P., Meyer, C. A., Brown, M. A., & Liu, X. S. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/106534 · Cited by 5
crisprQTL mapping as a genome-wide association framework for cellular genetic screensPreprint
Gasperini, M. J., Hill, A. J., McFaline‐Figueroa, J. L., Martin, B., Trapnell, C., Ahituv, N., & Shendure, J. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/314344 · Cited by 5
CRISPR-Cas9 interrogation of a putative fetal globin repressor in human erythroid cellsPreprint
Chung, J. E., Magis, W., Vu, J. T., Heo, S., Wartiovaara, K., Walters, M. C., Kurita, R., Nakamura, Y., Boffelli, D., Martin, D. I. K., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/335729 · Cited by 4
Self-citationGlaser, L. V., Steiger, M., Fuchs, A., van Bömmel, A., Einfeldt, E., Chung, H.-R., Vingron, M., & Meijsing, S. H. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.04.446899 · Cited by 5
Hara, Y., Kawabata, E., Lemgart, V. T., Bronson, P. G., Hicks, A., Peters, R., Krishnamoorthy, S., Ribeil, J., Schmunk, L. J., Eglinton, J., et al. (2023) · medRxiv · doi:10.1101/2023.03.14.23287244 · Cited by 4
In cellulo DNA assembly for targeted genomic integration and rearrangement in human cellsPreprint
Levesque, S., Kawashima, N., Hwang, G., Becerra, B., Schoonenberg, V. A. C., Mannherz, W. P., Homfeldt, L., Pinello, L., Agarwal, S., & Bauer, D. E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.16.659926 · Cited by 4
Self-citationMaroofi, N., Maleki, M. S. M., Tahmasebi, M., Khorshid, H. R. K., Modaberi, Y., Najafipour, R., & Banan, M. (2024) · Molecular Biotechnology · doi:10.1007/s12033-024-01155-0 · Cited by 3
Direct and indirect regulation of fetal globin transcript by the RNA-binding protein IGF2BP1
Coyne, S. M., Hwang, G.-H., Wu, T., Hossain, M. A., Vinjamur, D. S., Starrs, M. M., Zeng, J., Andresen, F., Gutierrez, A. M., Shimamura, A., et al. (2026) · Blood · doi:10.1182/blood.2025031840 · Cited by 4
Self-citationDetection of pre-existing immunity to bacterial Cas9 proteins in people with cystic fibrosis
Serpa, G., Gong, Q., De, M., Rana, P. S. J. B., Montgomery, C. P., Wozniak, D. J., Long, M. E., & Hemann, E. A. (2025) · ImmunoHorizons · doi:10.1093/immhor/vlaf041 · Cited by 3
Boccacci, Y., Dumont, N., Doyon, Y., & Laganière, J. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.07.007 · Cited by 3
Applications of gene modification technologies in the treatment of inherited diseases
Superson, M., Szmyt, K., Wilk-Trytko, K., Krasnoborska, J., Samojedny, S., Szymańska, K., & Walczak, K. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.66.002 · Cited by 3
Moeckel, C. M., Mouratidis, I., Chantzi, N., Uzun, Y., & Georgakopoulos‐Soares, I. (2024) · BioEssays · doi:10.1002/bies.202300210 · Cited by 4
Thalassemia Disorders: A Scoping Insight toward Management and Patient Care Prospects
Al‐Taie, A., Ürek, A., Kayas, H., & Tahir, H. (2024) · Journal of Preventive Diagnostic and Treatment Strategies in Medicine · doi:10.4103/jpdtsm.jpdtsm_56_24 · Cited by 3
Takezaki, M., Li, Y., Xu, H., Patel, N., Lucas, R., Cerbone, R. E., Koti, S., Hendrick, C. L., Junker, L. H., & Pace, B. S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0323550 · Cited by 3
Pan, C., Li, R., Shui, L., Xiao, Z., Wang, Y., Zhu, J., Wu, C., Zhang, L., Jia, J., & Zheng, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad198 · Cited by 4
Fañanas-Baquero, S., Morin, M., Fernández, S., Ojeda-Pérez, I., Dessy-Rodríguez, M., Giurgiu, M., Bueren, J. A., Moreno-Pelayo, M. Á., Segovia, J. C., & Bustamante, O. Q. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1104666 · Cited by 3
MMCT-Loop: a mix model-based pipeline for calling targeted 3D chromatin loops
Tang, L., Liao, J., Hill, M., Hu, J., Zhao, Y.-C., Ellinor, P., & Li, M. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae029 · Cited by 3
Challenges and Outlooks in Precision Medicine: Expectations Versus Reality
Yan, R., & Greenfield, J. P. (2024) · World Neurosurgery · doi:10.1016/j.wneu.2024.06.142 · Cited by 3
Role of B-Cell Lymphoma/Leukemia 11A in Normal and Malignant Hematopoiesis
Zhang, H., Zeng, J., Zhang, F., Liu, J., & Liang, L. (2025) · Biology · doi:10.3390/biology14010026 · Cited by 4
Self-citationSong, M., Wei, X., Luo, H., Wang, J., Ye, Y., Qin, L., Niu, C., Long, Y., Wang, X., Shao, C., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024013695 · Cited by 3
Cellular Thermal Shift Analysis for Interrogation of CRISPR-Assisted Proteomic Changes
Her, N.-G., Babić, I., Yenugonda, V. M., Kesari, S., & Nurmemmedov, E. (2020) · BioTechniques · doi:10.2144/btn-2019-0100 · Cited by 3
He, Y., Luo, J., Chen, Y., Zhou, X., Yu, S., Jin, L., Xiao, X., Jia, S., & Liu, Q. (2017) · Molecular Genetics and Genomics · doi:10.1007/s00438-017-1377-2 · Cited by 3
Daniel-Moreno, A., Lamsfus‐Calle, A., Wilber, A. C., Chambers, C. B., Johnston, I., Antony, J. S., Epting, T., Handgretinger, R., & Mezger, M. (2020) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2020.102456 · Cited by 3
Versatile and robust genome editing with Streptococcus thermophilus CRISPR1-Cas9Preprint
Agudelo, D., Carter, S., Velimirovic, M., Duringer, A., Levesque, S., Rivest, J.-F., Loehr, J., Mouchiroud, M., Cyr, D., Waters, P. J., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/321208 · Cited by 3
How CRISPR Is Revolutionizing the Generation of New Models for Cancer ResearchPreprint
Rivera, F. J. S., & Dow, L. E. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041384 · Cited by 4
Scalable assessment of genome editing off-targets associated with genetic variantsPreprint
Lin, J., Nguyen, M. A., Lin, L. Y., Zeng, J., Verma, A., Neri, N. R., da Silva, L. F., Mucci, A., Wolfe, S. A., Shaw, K. L., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.24.605019 · Cited by 3
Self-citationUmhoefer, J. M., Arce, M. M., Whalen, S., Dajani, R., Goudy, L., Kasinathan, S., Belk, J. A., Zhang, W., Zhou, R., Subramanya, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.30.610436 · Cited by 3
Scaling perturbations: beyond genome-scale CRISPR screensPreprint
Tang, A., Ardy, R. C., Mendes, R., & Norman, T. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.16.699948 · Cited by 4
Rivest, J.-F., Carter, S., Goupil, C., Antérieux, P., Cyr, D., Ung, R., Soglio, D. B. D., Mac‐Way, F., Waters, P. J., Paganelli, M., et al. (2024) · Genetics · doi:10.1093/genetics/iyae139 · Cited by 3
Expanding the CRISPR/Cas toolkit: applications in proteomics and theranostics
Punde, A., Dey, S., Pandire, R., Bhattacharjee, A., & Patra, C. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1713700 · Cited by 2
Molecular systems, human noncoding sequence variants, and blood pressure
Qiu, Q., & Liang, M. (2026) · Physiological Reviews · doi:10.1152/physrev.00029.2025 · Cited by 3
A Comprehensive Review on CRISPR-Based Screening and Its Applications
Sichani, A. S., Hassani, M., Gila, F., Shafieipour, N., Dabbaghipour, R., Heidari, Z., Sisakht, M., Hassani, M., & Fallahi, J. (2026) · Molecular Biotechnology · doi:10.1007/s12033-026-01562-5 · Cited by 2
Non-genotoxic transplantation and in vivo selection through epitope editing
Casirati, G., Cosentino, A., Freschi, M., Zeng, J., Mucci, A., Levesque, S., Neri, N. R., Drago, E., Carzaniga, V., Romano, F., et al. (2026) · Nature · doi:10.1038/s41586-026-10737-8 · Cited by 2
Self-citationGene therapy and editing in the treatment of hereditary blood disorders: Medical and ethical aspects
Alburquerque, P. C., Gómez‐Tatay, L., & Aznar, J. (2021) · Clinical Ethics · doi:10.1177/14777509211057255 · Cited by 2
Metadata
- Authors
- Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., Luc, S., Kurita, R., Nakamura, Y., Fujiwara, Y., Maeda, T., Yuan, G.-C., Zhang, F., Orkin, S. H., & Bauer, D. E.
- Affiliations
- Boston Children's Hospital (US)
- Harvard University (US)
- Broad Institute (US)
- RIKEN BioResource Research Center (JP)
- University of Tsukuba (JP)
- Brigham and Women's Hospital (US)
- Corresponding author
- Zhang, Feng
- Orkin, Stuart H.
- Bauer, Daniel E.
- ORCID
- Venue
- Nature
- Published
- 2015-09-16
- Volume
- 527
- Issue
- 7577
- Pages
- 192-197
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4644101
- OpenAlex
- W1855348513
- Cited by
- 886
- References
- 65
- Citations by year
- 2026: 43 · 2025: 72 · 2024: 76 · 2023: 79 · 2022: 68 · 2021: 91 · 2020: 85 · 2019: 92 · 2018: 87 · 2017: 94 · 2016: 89 · 2015: 8
- FWCI
- 51.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion)
- PMC
- Funders
- Howard Hughes Medical Institute
- U.S. Public Health Service (R01 A1084905)
- National Heart, Lung, and Blood Institute (P01HL032262, R01HL032259, R01HL119099)
- National Institute of Mental Health (DP1MH100706, R01MH110049)
- National Human Genome Research Institute (K99HG008171, R01HG005085, K99HG008399)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK049216, 5R01-DK097768, R01DK097768, F30DK103359, K08DK093705)
- National Center for Chronic Disease Prevention and Health Promotion (5DP1-MH100706)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- BCL11A, enhancers, CRISPR/Cas9, fetal hemoglobin, sickle cell disease, beta-thalassemia, enhancer architecture, erythroblasts
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, Animals, Base Sequence, Carrier Proteins, Cells, Cultured, DNA-Binding Proteins, Enhancer Elements, Genetic, Erythroblasts, Fetal Hemoglobin, Genetic Engineering, Humans, Molecular Sequence Data, Nuclear Proteins, Organ Specificity, Repressor Proteins, Species Specificity, Reproducibility of Results, Mutagenesis, Genome, Mice, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
